SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)
Por:
Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M
Publicada:
1 ene 2018
Resumen:
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
Filiaciones:
Cassinello J:
Medical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Arranz JÁ:
Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
Piulats JM:
Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
Sánchez A:
Medical Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Spain
Pérez-Valderrama B:
Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Mellado B:
Medical Oncology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain
Climent MÁ:
Medical Oncology Department, Fundacion Instituto Valenciano de Oncología, Valencia, Spain
Olmos D:
CNIO-IBIMA Genito-Urinary Cancer Unit, Medical Oncology Department, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga, Spain
Carles J:
Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Lázaro M:
Medical Oncology Department, Hospital Universitario de Vigo, Vigo, Spain
|